Dr. Yujin Xu 徐裕金
Chief Physician
Department of Thoracic Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for thoracic tumors, including esophageal, lung, and breast cancer. Proficient in SBRT, TOMO, and CyberKnife.
Dr. Xu holds an MD and serves as Deputy Director of the Department of Thoracic Radiation Oncology at Zhejiang Cancer Hospital. Dr. Xu graduated from Jilin University Bethune Medical College in 2001 and was a visiting scientist at M. D. Anderson Cancer Center from 2016 to 2017.
Professional roles
- Vice Chair, Committee on Radiation Oncology, China Medical Education Association
- Member, Young Committee, Branch of Radiation Oncology, Chinese Medical Association
- Member, Lung Cancer Group, Branch of Radiation Oncology, Chinese Medical Association
- Member, Lung Cancer Group, Professional Committee on Radiation Therapy, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Xu Yujin). Papers usually list the name as Yujin Xu or Xu Y.
Selected publications
59 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Clin Oncol, 2026 (senior author): NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002. PubMed 42555881
- J Thorac Dis, 2026 (senior author): Radiotherapy combined with third-generation EGFR tyrosine kinase inhibitor in first-line treatment of advanced oligometastatic non-small cell lung cancer: a single-center, retrospective study. PubMed 41660475
- ACS Appl Mater Interfaces, 2025 (senior author): Copper-Induced Cuproptosis and Immunogenic Cell Death Synergize with Radiotherapy and PD-1 Blockade in Osteosarcoma. PubMed 40763959
- World J Clin Oncol, 2025 (senior author): Safety and effectiveness of induction chemoimmunotherapy followed by definitive radiotherapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma. PubMed 40130057
- Lancet Oncol, 2025 (first author): Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. PubMed 39756446
- Sci Rep, 2024 (senior author): Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study. PubMed 39627240
- Front Oncol, 2022 (senior author): A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. PubMed 35982975
- Clin Cancer Res, 2022 (first author): A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma. PubMed 35190815
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion